Virus-encoded chemokines, chemokine receptors and chemokine-binding proteins: New paradigms for future therapy

Future Virology

Volumn 2, Issue 4, 2007, Pages 353-368

  Dagna, Lorenzo ^a,b   Lusso, Paulo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Chemokine receptors; Chemokines; Immunomodulation; Molecular piracy; Viruses

Indexed keywords

ALPHA CHEMOKINE; ANTIVIRUS AGENT; BETA CHEMOKINE; BINDING PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CX3C CHEMOKINE; CXCL1 CHEMOKINE; FLICE INHIBITORY PROTEIN; GAMMA CHEMOKINE; GLYCOSAMINOGLYCAN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; THROMBOSPONDIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANTIINFLAMMATORY ACTIVITY; BRAIN INFARCTION; CARDIAC GRAFT REJECTION; CELLULAR IMMUNITY; DNA VIRUS; DRUG TARGETING; GLOMERULONEPHRITIS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TH1 CELL; TH2 CELL; VIRUS IMMUNITY; VIRUS INFECTION;

DNA VIRUSES;

EID: 34447323277     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.2.4.353     Document Type: Review

References (99)

1. Alcami A, Koszinowski UH: Viral mechanisms of immune evasion. Immunol. Today 21(9), 447-455 (2000).
2. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL: Vital subversion of the immune system. Annu. Rev. Immunol. 18, 861-926 (2000).
3. Allen SJ, Crown SE, Handel TM: Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 25, 787-820 (2007).
4. Cinamon G, Shinder V, Alon R: Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat. Immunol. 2(6), 515-522 (2001).
5. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
6. Viola A, Contento RL, Molon B: T cells and their partners: the chemokine dating agency. Trends Immunol. 27(9), 421-427 (2006).
7. Lusso P: Chemokines and viruses: the dearest enemies. Virology 273(2), 228-240 (2000).
8. Alcami A: Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3(1), 36-50 (2003).
9. Lindow M, Nansen A, Bartholdy C et al.: The virus-encoded chemokine vMIP-H inhibits virus-induced Tcl-driven inflammation. J. Virol. 77(13), 7393-7400 (2003).
10. Singh UP, Singh S, Ravichandran P, Taub DD, Lillard JW Jr: Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts. J. Immunol. 173(9), 5509-5516 (2004).
11. Luttichau HR, Lewis IC, Gerstoft J, Schwartz TW: The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor. Eur. J. Immunol. 31(4), 1217-1220 (2001).
12. Tripp RA, Jones LP, Haynes LM et al.: CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2(8), 732-738 (2001).
13. + T cell responses. J. Immunol. 176(3), 1600-1608 (2006).
14. Dewin DR, Catusse J, Gompels UA: Identification and characterization of U83A viral chemokine, a broad and potent β-chemokine agonist for human CCRs with unique selectivity and inhibition by spliced isoform. J. Immunol. 176(1), 544-556 (2006).
15. Catusse J, Parry CM, Dewin DR, Gompels UA. Inhibition of HIV-1 infection by viral chemokine U83A via high affinity CCR5 interactions which block human chemokine-induced leukocyte chemotaxis and receptor internalisation. Blood (2007) (Epub ahead of print).
16. Luttichau HR, Clark-Lewis I, Jensen PO et al.: A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6. J. Biol. Chem. 278(13), 10928-10933 (2003).
17. Noda S, Aguirre SA, Bitmansour A et al.: Cytomegalovirus MCK-2 Controls mobilization and recruitment of myeloid progenitor cells to ficilirate dissemination. Blood 107(1), 30-38 (2006).
18. Saederup N, Aguirre SA, Sparer TE, Bouley DM, Mocarski ES: Murine cytomegalovirus CC chemokine homologue MCK-2 (m131-129) is a determinant of dissemination that increases inflammation at initial sites of infection. J. Virol. 75(20), 9966-9976 (2001).
19. Cui X, Lee LF, Reed WM, Kung HJ, Reddy SM: Marek's disease virus-encoded vIL-8 gene is involved in early cytolytic infection but dispensable for establishment of latency. J. Virol. 78(9), 4753-4760 (2004).
20. Louahed J, Struyf S, Demoulin JB et al.: CCR8-dependent activation of the RAS/MAPK pathway mediates antiapoptotic activity of I-309/CCL1 and vMIP-I. Eur. J. Immunol. 33(2), 494-501 (2003).
21. Seet BT, McFadden G: Viral chemokine-binding proteins. J. Leukoc. Biol. 72(1), 24-34 (2002).
22. Carfi A, Smith CA, Smolak PJ, McGrew J, Wiley DC: Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc. Natl Acad. Sci. USA 96(22), 12379-12383 (1999).
23. Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ: Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics. J. Biol. Chem. 277(4), 2785-2789 (2002).
24. Alexander JM, Nelson CA, van Berkel V et al.: Structural basis of chemokine sequestration by a herpesvirus decoy receptor. Cell 111(3), 343-356 (2002).
25. Wang D, Bresnahan W, Shenk T: Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc. Natl Acad. Sci. USA 101(47), 16642-16647 (2004).
26. Lalani AS, Graham K, Mossman K et al.: The purified myxoma virus y interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J. Vvirol. 71(6), 4356-4363 (1997).
27. Alcami A, Symons JA. Collins PD, Williams TJ, Smith GL: Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160(2), 624-633 (1998).
28. Smith CA, Smith TD, Smolak PJ et al.: Poxvirus genomes encode a secreted, soluble protein that preferentially inhibits beta chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 236(2), 316-327 (1997).
29. Seet BT, Singh R, Paavola C et al.: Molecular determinants for CC-chemokine recognition by a Poxvirus CC-chemokine inhibitor. Proc. Natl. Acad. Sci USA 98(16), 9008-9013 (2001).
30. Beck CG, Studer C, Zuber JF et al.: The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site. J. Biol. Chem. 276(46), 43270-43276 (2001).
31. Seet BT, Barrett J, Robichaud J et al.: Glycosaminoglycan binding properties of the myxoma virus CC-chemokine inhibitor. M-T1. J. Biol. Chem. 276(32), 30504-30513 (2001).
32. Zhang L, Derider M, McCornack MA et al.: Solution structure of the complex between poxvirus-encodod CC chemokine inhibitor vCCI and human MIP-1β. Proc. Natl Acad. Sci. USA 103(38), 13985-13990 (2006).
33. Parry CM, Simas JP, Smith VP et al.: A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med. 191(3), 573-578 (2000).
34. van Berkel V, Barrett J, Tiffany HL et al.: Identification of a γ-herpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 74(15), 6741-6747 (2000).
35. Alcami A. Structural basis of the herpesvirus M3-chemokine interaction. Trends Microbiol. 11(5), 191-192 (2003).
36. Bridgeman A, Stevenson PG, Simas JP, Efstathiou S: A secreted chemokine-binding protein encoded by murine γ-herpesvirus-68 is necessary for the establishment of a normal latent load. J. Exp. Med. 194(3), 301-312 (2001).
37. Webb LM, Clark-Lewis I, Alcami A: The γ-herpesvirus chemokine binding protein binds to the N terminus of CXCL8. J. Virol. 77(15), 8588-8592 (2003).
38. Jensen KK, Chen SC, Hipkin RW et al.: Disruption of CCL21-induced chemotaxis in vitro and in vivo by M3, a chemokine-binding protein encoded by murine γherpesvirus 68. J. Virol. 77(1), 624-630 (2003).
39. van Berkel V, Levine B, Kapadia SB et al.: Critical role for a high-affinity chemokine-binding protein in γ-herpesvirus-induced lethal meningitis. J. Clin. Invest. 109(7), 905-914 (2002).
40. Bryant NA, Davis-Poynter N, Vanderplasschen A, Alcami A: Glycoprotein-G isoforms from some α-herpesviruses fitnction as broad-spectrum chemokine binding proteins. EMBO J. 22(4), 833-846 (2003).
41. Costes B, Ruiz-Arguello MB, Bryant NA, Alcami A, Vanderplasschen A: Both soluble and membrane-anchored forms of Felid herpesvirus 1 glycoprotein G function as a broad-spectrum chemokine-binding protein. J. Gen. Virol. 86(Pt 12), 3209-3214 (2005).
42. Costes B, Thirion M, Dewals B et al.: Felid herpesvirus 1 glycoprotein-G is a structural protein that mediates the binding of chemokines on the viral envelope. Microbes Inject. 8(11), 2657-2667 (2006).
43. Seet BT, McCaughan CA, Handel TM et al.: Analysis of an orf virus chemokine-binding protein: shifting ligand specificities among a family of Poxvirus viroceptors. Proc. Natl. Acad. Sci. USA 100(25), 15137-15142 (2003).
44. Seet BT, Johnston JB, Brunetti CR et al.: Porviruses and immune evasion. Annu. Rev. Immunol. 21, 377-423 (2003).
45. Alejo A, Ruiz-Arguello MB, Ho Y et al.: A chemokine-binding domain in the tumor necrosis factor receptor from Variola (smallpox) virus. Proc. Natl Acad. Sci USA 103(15), 5995-6000 (2006).
46. Kunkel EJ, Butcher EC: Chemokines and the tissue-specific migration of lymphocytes. Immunity 16(1), 1-4 (2002).
47. Schaerli P, Willimann K, Ebert LM, Walz A, Moser B: Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23(3), 331-342 (2005).
48. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW: Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J. Biol. Chem. 274(2), 956-961 (1999).
49. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E: Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385(6614), 347-350 (1997).
50. Chiou CJ, Poole LJ, Kim PS et al.: Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvinis. J. Virol. 76(7), 3421-3439 (2002).
51. Cannon M, Philpott NJ, Cesarman E: The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J. Virol. 77(1), 57-67 (2003).
52. Montaner S, Sodhi A, Molinolo A et al.: Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3(1), 23-36 (2003).
53. Bais C, Van Geelen A, Eroles P et al.: Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3(2), 131-143 (2003).
54. Verzijl D, Pardo L, van Dijk M et al.: Helix 8 of the viral chemokine receptor ORF74 directs chemokine binding. J. Biol. Chem. 281(46), 35327-35335 (2006).
55. Holst PJ, Rosenkilde MM, Manfra D et al.: Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J. Clin. Invest. 108(12), 1789-1796 (2001).
56. Polson AG, Wang D, DeRisi J, Ganem D: Modulation of host gene expression by the constitutively active G protein-coupled receptor of Kaposi's sarcoma-associated herpcsvirus. Cancer Res. 62(15), 4525-4530 (2002).
57. Jensen KK, Manfra DJ, Grisotto MG et al.: The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J. Immunol. 174(6), 3686-3694 (2005).
58. Grisotto MG, Garin A, Martin AP et al.: The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J. Clin. Invest. 116(5), 1264-1273 (2006).
59. Malnati MS, Dagna L, Ponzoni M, Lusso P: Human herpesvirus 8 (HHV-8/ KSHV) and hematologic malignancies. Rev. Clin. Exp. Hematol. 7(4), 375-405 (2003).
60. Pati S, Cavrois M, Guo HG et al.: Activation of NF-κB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J. Virol. 75(18), 8660-8673 (2001).
61. Schwarz M, Murphy PM: Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-κB and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. J. Immunol. 167(1), 505-513 (2001).
62. Liu C, Okruzhnov Y, Li H, Nicholas J: Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) m HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J. Virol. 75(22), 10933-10940 (2001).
63. Estep RD, Axthelm MK, Wong SW: A G protein-coupled receptor encoded by rhesus rhadinovirus is similar to ORF74 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 77(3), 1738-1746 (2003).
64. Casarosa P, Bakker RA, Verzijl D et al.: Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J. Biol. Chem. 276(2), 1133-1137 (2001).
65. McLean KA, Holst PJ, Martini L, Schwartz TW, Rosenkilde MM: Similar activation of signal transduction pathways by the herpesvirus-encoded chemokine receptors US28 and ORF74. Virology 325(2), 241-251 (2004).
66. Boomker JM, The TH, de Leij LF, Harmsen MC: The human cytomegalovirus-encoded receptor US28 increases the activity of the major immediate-early promoter/enhancer. Virus Res. 118(1-2), 196-200 (2006).
67. Maussang D, Verzijl D, van Walsum M et al.: Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl Acad. Sci. USA 103(35), 13068-13073 (2006).
68. Fitzsimons CP, Gompels UA, Verzijl D et al.: Chemokine-directed trafficking of receptor stimulus to different G proteins: selective inducible and constitutive signaling by human herpesvirus 6-encoded chemokine receptor U51. Mol. Pharmacol. 69(3), 888-898 (2006).
69. Waldhoer M, Kledal TN, Farrell H, Schwartz TW: Murine cytomegalovirus (CMV) M33 and human CMV US28 receptors exhibit similar constitutive signaling activities. J. Virol. 76(16), 8161-8168 (2002).
70. Gruijthuijsen YK, Casarosa P, Kaptein SJ et al.: The rat cytomegalovirus R33-encoded G protein-coupled receptor signals in a constitutive fashion. J. Virol. 76(3), 1328-1338 (2002).
71. Tadagaki K, Nakano K, Yamanishi K: Human herpesvirus 7 open reading frames U12 and U51 encode functional β-chemokine receptors. J. Virol. 79(11), 7068-7076 (2005).
72. Nakano K, Tadagaki K, Isegawa Y et al.: Human herpesvirus 7 open reading frame U12 encodes a functional β-chemokine receptor. J. Virol. 77(14), 8108-8115 (2003).
73. Lupu-Meiri M, Silver RB, Simons AH, Gershengorn MC, Oron Y: Constitutive signaling by Kaposi's sarcoma-associated herpesvirus G-protein-coupled receptor desensitizes calcium mobilization by other receptors. J. Biol. Chem. 276(10), 7122-7128 (2001).
74. Randolph-Habecker JR, Rahill B, Torok-Storb B et al.: The expression of the cytomegalovirus chemokine receptor homolog US28 sequesters biologically active CC chemokines and alters IL-8 production. Cytokine 19(1), 37-46 (2002).
75. Bodaghi B, Jones TR, Zipeto D et al.: Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J. Exp. Med. 188(5), 855-866 (1998).
76. Boomker JM, van Luyn MJ, The TH, de Leij LF, Harmsen MC: US28 actions in HCMV infection: lessons from a versatile hijacker. Rev. Med. Virol. 15(4), 269-282 (2005).
77. Milne RS, Mattick C, Nicholson L et al.: RANTES binding and down-regulation by a novel human herpesvirus-6 β-chemokine receptor. J. Immunol. 164(5), 2396-2404 (2000).
78. Streblow DN, Soderberg-Naucler C, Vieira J et al.: The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99(5), 511-520 (1999).
79. Streblow DN, Vomaske J, Smith P et al.: Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J. Biol. Chem. 278(50), 50456-50465 (2003).
80. Melnychuk RM, Smith P, Kreklywich CN et al.: Mouse cytomegalovirus M33 is necessary and sufficient in virus-induced vascular smooth muscle cell migration. J. Virol. 79(16), 10788-10795 (2005).
81. Kledal TN, Rosenkilde MM, Schwartz TW: Selective recognition of the membrane-bound CX3C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28. FEBS Lett. 441(2), 209-214 (1998).
82. Vischer HF, Leurs R, Smit MJ: HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci. 27(1), 56-63 (2006).
83. Haskell CA, Cleary MD, Chato IF: Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J. Biol. Chem. 275(44), 34183-34189 (2000).
84. Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S: The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulate virus replication and enhances cell-cell fusion in vitro. J. Virol. 79(18), 11914-11924 (2005).
85. Fraile-Ramos A. Pelchen-Matthews A, Kledal TN et al.: Localization of HCMV UL33 and US27 in endocytic compartments and viral membranes. Traffic 3(3), 218-232 (2002).
86. Fraile-Ramos A, Kledal TN, Pelchen-Matthews A et al.: The human cytomegalovirus US28 protein is located in endocytic vesicle and undergoes constitutive cridocytosis and recycling. Mol. Biol. Cell. 12(6), 1737-1749 (2001).
87. Pleskoff O, Casarosa P, Verneuil L et al.: The human cytomegalovirus-encoded chemokine receptor US28 induces caspase-dependent apoptosis. FEBS J. 272(16), 4163-4177 (2005).
88. Lucas A, McFadden G: Secreted immunomodulatory viral proteins as novel biotherapeutics. J. Immunol. 173(8), 4765-4774 (2004).
89. Fallon PG, Alcami A: Pathogen-derived immunomodulatory molecules: future immunotherapeutics? Trends Immunol. 27(10), 470-476 (2006).
90. DeBruyne LA, Li K, Bishop DK, Bromberg JS: Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther. 7(7), 575-582 (2000).
91. Takami S, Minami M, Nagata I, Namura S, Satoh M: Chemokine receptor antagonist peptide, viral MIP-II, protects the brain against focal cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 21(12), 1430-1435 (2001).
92. Ghirnikar RS, Lee YL, Eng LF: Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat. J. Neurosci. Res. 59(1), 63-73 (2000).
93. Chen S, Bacon KB, Li L et al.: In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulo nephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J. Exp. Med. 188(1), 193-198 (1998).
94. Liu L, Lalani A, Dai E et al.: The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J. Clin. Invest. 105(11), 1613-1621 (2000).
95. Bedard EL, Kim P, Jiang J et al.: Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts. Transplantation 76(1), 249-252 (2003).
96. Liu L, Dai E, Miller L et al.: Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models. Transplantation 77(11), 1652-1660 (2004).
97. Dabbagh K, Xiao Y, Smith C et al.: Local blockade of allergic airway hyperreactivity and inflammation by the Paxvirus-derived pan-CC-chemokine inhibitor vCCI. J. Immunol. 165(6), 3418-3422 (2000).
98. Jamieson T, Cook DN, Nibbs RJ et al.: The chemokine receptor D6 limits the inflammatory response in vivo. Nat. Immunol. 6(4), 403-411 (2005).
99. Pyo R, Jensen KK, Wiekowski MT et al.: Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. Am. J. Pathol. 164(6), 2289-2297 (2004).